Given that the cancer associated mutations in Cdc42 are not likely to predominantly affect deactivation mechanisms, as is found for K-Ras [10], selectivity for Cdc42 in both nucleotide forms may have therapeutic relevance. This evidence concerns the gene CDC42 and cancer.